This Article Full Text Full Text (PDF) All Versions of this Article: 93/1/19    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gooren, L. J. Articles by Bunck, M. C. Search for Related Content PubMed PubMed Citation Articles by Gooren, L. J. Articles by Bunck, M. C. Related Collections Calcium and Bone Metabolism Cardiovascular Endocrinology Endocrine Oncology Female Endocrinology

Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience

Department of Endocrinology (L.J.G., M.C.B.), Vrije Universiteit University Medical Center, 1081 HV Amsterdam, The Netherlands; and Leiden University Medical Center (E.J.G.), Department of Psychiatry, 2333 ZA Leiden, The Netherlands

Address all correspondence and requests for reprints to: Dr. L. J. Gooren, Department of Endocrinology, VU University Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands. E-mail: ljgooren{at}truemail.co.th.

Context: Transsexuals receive cross-sex hormone treatment. Its short-term use appears reasonably safe. Little is known about its long-term use. This report offers some perspectives.

Setting: The setting was a university hospital serving as the national referral center for The Netherlands (16 million people).

Patients: From the start of the gender clinic in 1975 up to 2006, 2236 male-to-female and 876 female-to-male transsexuals have received cross-sex hormone treatment. In principle, subjects are followed up lifelong.

Interventions: Male-to-female transsexuals receive treatment with the antiandrogen cyproterone acetate 100 mg/d plus estrogens (previously 100 µg ethinyl estradiol, now 2–4 mg oral estradiol valerate/d or 100 µg transdermal estradiol/d). Female-to-male transsexuals receive parenteral testosterone esters 250 mg/2 wk. After 18–36 months, surgical sex reassignment including gonadectomy follows, inducing a profound hypogonadal state.

Main Outcome Measures: Outcome measures included morbidity and mortality data and data assessing risks of osteoporosis and cardiovascular disease.

Results: Mortality was not higher than in a comparison group. Regarding morbidity, with ethinyl estradiol, there was a 6–8% incidence of venous thrombosis, which is no longer the case with use of other types of estrogens. Continuous use of cross-sex hormones is required to prevent osteoporosis. Androgen deprivation plus an estrogen milieu in male-to-female transsexuals has a larger deleterious effect on cardiovascular risk factors than inducing an androgenic milieu in female-to-male transsexuals, but there is so far no elevated cardiovascular morbidity/mortality. Low numbers of endocrine-related cancers have been observed in male-to-female transsexuals.

Conclusions: Cross-sex hormone treatment of transsexuals seems acceptably safe over the short and medium term, but solid clinical data are lacking.

This article has been cited by other articles:

				C. L Shufelt and G. D Braunstein Testosterone and the breast Menopause Int, September 1, 2008; 14(3): 117 - 122. [Abstract] [Full Text] [PDF]

				E. Resmini, G. Andraghetti, A. Rebora, R. Cordera, L. Vera, M. Giusti, F. Minuto, and D. Ferone Leptin, Ghrelin, and Adiponectin Evaluation in Transsexual Subjects During Hormonal Treatments J Androl, September 1, 2008; 29(5): 580 - 585. [Abstract] [Full Text] [PDF]